Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
Axsome Therapeutics has resolved all patent litigation related to its CNS drug SUNOSI (solriamfetol) by settling with the last remaining first-to-file generic applicant. The agreement grants five companies the right to sell generic versions of SUNOSI starting no earlier than March 1, 2040, or September 1, 2040, if pediatric exclusivity is granted.
Key figures
- Number of generic applicants settled
- 5
- Generic entry date with pediatric exclusivity
- September 1, 2040
- Generic entry date without pediatric exclusivity
- March 1, 2040
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.